Portfolio

CSP has built an innovative, differentiated and late-stage pipeline of products, focused on rare disease and ophthalmology targeting indications with significant unmet needs in China 

Rare disease

• China is undergoing dramatic change from a market which ten years ago was broadly focussed on generic drugs to a market where patent protected innovative speciality products are becoming the norm
• 1,423 rare diseases have been identified in China with 20 million rare disease patients with a market potential of $25.9bn USD
• Currently however only about 20% of approved rare disease drugs by the US FDA are approved in China
• Changes to the regulatory environment are seeking to ensure novel speciality products are brought to China within a short window from US/ EMA approval.
• Reimbursement landscape is changing with 2/3 of approved rare disease products in China now being reimbursed. China are currently looking at new models to fund ultra-high cost medicines through commercial insurance plans

Ophthalmology

• Ophthalmology is a huge opportunity and unmet need in China, where the ophthalmology market is growing at an average of around 22% a year 
• One third of the world’s blindness occurs in China and there is a government initiative to train more ophthalmologists over the next few years 
• Changes to the regulatory environment are seeking to ensure novel speciality products are brought to China within a short window from US/ EMA approval. 
• Abbreviated clinical development plans can be agreed leveraging clinical data generated in USA/ EU when there is unmet need in China